Previous 10 | Next 10 |
Immatics press release (NASDAQ:IMTX): Q1 GAAP EPS of €$1.35. Revenue of €102.91M (+1290.7% Y/Y). Shares up 16% PM. Cash and cash equivalents as well as other financial assets of $280.5M (€252.7M) as of March 31, 2022. With the upfront payment from...
ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with 2 nd -generation IMA203CD8 granted Phase 1 clinical trial initiated with th...
New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo ® with Bristol Myers Squibb’s technologies and o...
Immatics (NASDAQ:IMTX) said the first patient was dosed in a phase 1b dose expansion group evaluating its TCR-engineered cell therapy IMA203 with Bristol Myers Squibb's (BMY) Opdivo (nivolumab) to treat patients with advanced solid tumors. The company said the beginni...
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1 , a PD-1 immune checkpoint inhibitor, in patients with multiple solid tumors Initiation of the combination t...
Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors TCER® IMA401 targets MAGEA4/8 and will be de...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Immatics press release (NASDAQ:IMTX): FY GAAP EPS of -€1.48. Revenue of €34.76M (+11.2% Y/Y). For further details see: Immatics GAAP EPS of -$1.48 beats by €0.19, revenue of €34.76M
IMA203 TCR-T candidate targeting PRAME demonstrated a 50 % objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation M ultiple IMA203 Ph ase 1b expansion coh...
Immatics N.V. (IMTX +10.2%) has recorded the biggest gain since May after announcing an agreement with Bristol Myers Squibb (NYSE:BMY) for the licensing, development, and commercialization of the company’s TCR Bispecific candidate IMA401. Per the terms, Immatics (NASDAQ:IMTX) will...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...